Company Filing History:
Years Active: 2021
Title: Cuncheng Weng: Innovator in Urine-Modified Nucleoside Detection
Introduction
Cuncheng Weng is a notable inventor based in Fujian, China. He has made significant contributions to the field of medical diagnostics, particularly in the detection of urine-modified nucleosides. His innovative approach utilizes advanced spectroscopy techniques to enhance diagnostic accuracy.
Latest Patents
Cuncheng Weng holds a patent for a "Detection and analysis method for urine-modified nucleoside based on surface-enhanced resonance Raman spectroscopy." This invention presents a method for extracting tumor marker modified nucleosides from urine samples of both normal individuals and cancer patients. By employing borophenylic acid gel for specificity and Au colloid as an enhancing substrate, the method detects SERRS signals effectively. The statistical analysis using PLS-DA algorithms establishes a diagnostic model that can differentiate between normal and cancerous urine-modified nucleosides. The model boasts a specificity of 96.9%, sensitivity of 98.2%, and accuracy of 97.6%. This rapid and objective detection method provides crucial insights for doctors diagnosing esophagus cancer.
Career Highlights
Cuncheng Weng is affiliated with Fujian Normal University, where he continues to advance research in medical diagnostics. His work has garnered attention for its potential impact on cancer detection and patient care.
Collaborations
Cuncheng Weng collaborates with colleagues such as Shangyuan Feng and Zuci Zheng, contributing to a dynamic research environment focused on innovative diagnostic solutions.
Conclusion
Cuncheng Weng's contributions to the field of medical diagnostics through his patented methods highlight the importance of innovation in healthcare. His work not only enhances diagnostic capabilities but also offers hope for improved cancer detection and treatment.